Cardiovascular Surgery News
Scientific and Information Journal

a:2:{s:4:"TEXT";s:162:"The effect of cardiac shock wave therapy on the clinical and functional state of patients with coronary heart disease after myocardial revascularization surgery";s:4:"TYPE";s:4:"HTML";}

Authors: Borbodoeva B.M.1, Asymbekova E.U.1, Matskeplishvili S.T.1.2, Akhmedyarova N.K.1, Sherstyannikova O.M.1, Tugeeva E.F.1, Buziashvili V.Yu.1, Buziashvili Yu.I.1

1 Clinical and Diagnostic Department, Bakоulev National Medical Research Center of Cardiovascular Surgery, Rublevskoe shosse, 135, Moscow, 121552, Russian Federation;
2 Lomonosov Moscow State University Medical Center, Lomonosovskiy prospekt, 27/2, Moscow, 119192, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

Heading: Original Research

UDC: 616.12-005.4:616.127-089.844:615.8

Link: Clinical Physiology of Blood Circulaiton. 2019; 3 (2): 94-102

Quote as: Borbodoeva B.M., Matskeplishvili S.T., Asymbekova E.U., Akhmediarova N.K., Sherstyannikova O.M., Tugeeva E.F., Buziashvili V.Yu., Buziashvili Yu.I. The effect of cardiac shock wave therapy on the clinical and functional state of patients with coronary heart disease after myocardial revascularization surgery. Cardiovascular Surgery News. 2019; 3 (2): 94–102 (in Russ.). DOI: 10.24022/2588-0284-2019-3-2-94-102

Received / Accepted:  31.05.2019/24.06.2019

Full text:
Subscribe 🔒


Summary. A significant number of patients with ischemic heart disease (CAD) after myocardial revascularization persist withsymptoms of angina, which causes a deterioration in the prognosis and quality of life of patients. In many cases, the features of CAD do not allow repeated myocardial revascularization, and the presence of comorbidity is associated with an unacceptably high risk of perioperative complications. Such problems dictate the use of alternative therapeutic approaches, including cardiac shock wave therapy (CSWT) – one of the new methods that allow non-invasive stimulation of angiogenesis in the area of myocardial ischemia.

Objective. To study the possibility of using shock-wave therapy in patients with coronary heart disease after myocardial revascularization, as well as to assess its safety and effectiveness.

Material and Methods. 50 patients with CAD with reversible left ventricular myocardial dysfunction according to stress echocardiography were examined. Aorto-coronary bypass surgery (CABG) was performed in 71% of patients, 12% underwent percutaneous coronary intervention, 17% of patients did not tolerate myocardial revascularization. The CSWT was conducted according to the standard method. All patients when included in the study, immediately after the end and a month after the course of CSWT, were carried out a comprehensive clinical and instrumental examination and laboratory examination. To assess the safety of CSWT, the levels of troponin I, a cardiac protein, binding aliphatic acids, C-reactive protein (CRP) were determined; For evaluation of angiogenesis, vascular endothelial growth factor A (VEGF-A), hepatocyte growth factor (HGF), fibroblast growth factor (FGF basic), transforming growth factor alpha (TGF-α).

Results. After the completed course of CSWT according to the standard scheme, patients had a significant decrease in the average functional class of angina, improved longitudinal systolic function and diastolic function of the myocardium. There was an increase in EF from 53.9±1.0% to 56.4±0.8%, according to the stress-Echo, a significant increase in load time was observed from 5.5±0.1 minutes to 6.8±0.1 and 7.7±0.2 minutes, respectively. The increase in EF in response to the load was 10.3±1.5% at baseline, after CSWT – 14.4±1.1%, and after 1 month – 17.1±1.3%. According to tissue Doppler, there was a significant improvement in the longitudinal systolic and diastolic functions of the myocardium. The dynamics of laboratory examinations before and after CSWT showed a significant increase in the content of all growth factors after the 3rd session and the preservation of the achieved gain 1 month after the end of therapy. When comparing the degree of change in the concentration of growth factors, the minimum increase in the level of angiogenesis factors was 1.6, the maximum – 2.2. When studying the dynamics of troponin I, cardiac protein, binding aliphatic acids, C-reactive protein, no negative dynamics were observed in any case.

Conclusion. The use of shock-wave therapy in patients with coronary artery disease is accompanied by an improvement in functional status, which is manifested in an increase in the tolerance threshold and duration of the load, an increase in EF in response to the load. CSWT leads to improvement of longitudinal systolic function, improvement of diastolic function. The basis for improving the clinical and functional state is the mechanism of angiogenesis, confirmed by an increase in the content of angiogenic factors. In no case was there any worsening of the condition of the patients, no negative dynamics of the diastolic and systolic functions of the ventricles was observed, which characterizes the CSWT as a safe method. Additionally, safety is confirmed by the determination of troponin I, cardiac protein, binding aliphatic acids, and CRP.


  1. Бокерия Л.А., Гудкова Р.Г. Болезни и врожденные аномалии системы кровообращения. Грудная и сердечно-сосудистая хирургия. 2012; 6: 24–57.
  2. Clinical trial – COURAGE 2007. N. Engl. J. Med. 2007; 356. DOI: 10.1016/j.amjcard.2006.07.082
  3. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. New England J. Med. 2009; 360 (24): 2503–15. DOI: 10.1056/NEJMoa0805796
  4. Бокерия Л.А., Голухова Е.З., Еремеева М.В., Георгиев Г.П., Киселев С.Л., Мерзляков В.Ю. и др. Новые подходы к лечению ишемической болезни сердца: терапевтический ангиогенез в сочетании с хирургической реваскуляризацией миокарда. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2004; 5 (5): 71.
  5. Бузиашвили Ю.И., Ключников Ю.И., Асымбекова Э.У. и др. Геометрические критерии диагностики жизнеспособности миокарда. Российские биомедицинские исследования. 2001; 6 (1): 90–7.
  6. Бокерия Л.А., Работников В.С., Бузиашвили Ю.И. Ишемическая болезнь сердца у больных с низкой сократительной способностью миокарда левого желудочка (диагностика, тактика лечения). М.: НЦССХ им. А.Н. Бакулева; 2001.
  7. Васюк Ю.А., Хадзегова А.Б., Школьник Е.В., Несветов В.В., Щербак М.М., Селезнёва М.Г. Ударно-волновая терапия сердца: особенности механизма действия и возможности применения. Доктор.Ру. 2013; 10: 14–9.
  8. Kaller M., Faber L., Bogunovic N., Horstkotte D., Burchert W., Lindner O. Cardiac shock wave therapy and myocardial perfusion in severe coronary artery disease. Clin. Res. Cardiol. 2015; 10: 1–7. DOI: 10.1007/s00392-015-0853-0
  9. Nishida T., Shimokawa H., Oi K., Tatewaki H., Uwatoku T., Abe K. et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004; 110 (19): 3055–61. DOI: 10.1161/01.CIR.0000148849.51177.97
  10. Mariotto S., Cavalieri E., Amelio E., Ciampa A.R., de Prati A.C., Marlinghaus E. et al. Extracorporeal shock waves: from lithotripsy to anti-inflammatory action by NO production. Nitric. Oxide. 2005; 12 (2): 89–96. DOI: 10.1016/j.niox.2004.12.005
  11. Caspari G.H., Erbel R. Revascularization with extracorporeal shock wave therapy: first clinical results. Circulation. 1999; 100 (Suppl. 18): 84.
  12. Alunni G., Marra S., Meynet I., D'Amico M., Pelloni E., Fanelli A. et al. The beneficial effect of extracorporeal shockwave myocardial revascularization in patients with refractory angins. Cardiovasc. Revasc. Med. 2015; 16 (1): 6–11. DOI: 10.1016/j.carrev.2014.10.011
  13. Wang Y., Guo T., Cai H.Y., Ma T.K., Tao S.M., Sun S. et al. Cardiac shock wave therapy reduces angina and improves myocardial function in patients with refractory coronary artery disease. Clin. Cardiol. 2010; 33 (11): 693–9. DOI: 10.1002/clc.20811
  14. Fukumoto Y., Ito A., Uwatoku T., Matoba T., Kishi T., Tanaka H. et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron. Artery Dis. 2006; 17 (1): 63: 70.
  15. Wang C.J., Wang F.S., Yang K.D., Weng L.H., Hsu C.C., Huang C.S. et al. Shock wave therapy induces neovascularization at the Tendon-Bone junction. A study in rabbits. J. Orthop. Res. 2003; 21 (6): 984–9. DOI: 10.1016/S0736-0266(03)00104-9
  16. Holfeld J., Zimpfer D., Albrecht-Schgoer K., Stojadinovic A., Paulus P., Dumfarth J., Schaden W. Epicardial shock-wave therapy improves ventricular function in a porcine model of ischaemic heart disease. J. Tissue Eng. Regen. Med. 2016; 10 (12): 1057–64. DOI: 10.1002/term.1890
  17. Yang W., He Y., Gan L., Zhang F., Hua B., Yang P. et al. Cardiac shock wave therapy promotes arteriogenesis of coronary micrangium and ILK is involved in the biomechanical effects by proteomic analysis. Scientific Reports. 2018; 8 (1): 1814. DOI: 10.1038/s41598-018-19393-z
  18. Tepeköylü C., Wang F.S., Kozaryn R., Albrecht-Schgoer K., Theurl M., Schaden W. Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis. J. Thorac. Cardiovasc. Surg. 2013; 146 (4): 971–8. DOI: 10.1016/j.jtcvs.2013.01.017
  19. Ito K., Fukumoto Y., & Shimokawa H. Extracorporeal shock wave therapy for ischemic cardiovascular disorders. Am. J. Cardiovasc. Drugs. 2011; 11 (5): 295–302. DOI: 10.2165/11592760
  20. Yang P., Guo T., Wang W., Peng Y.Z., Wang Y., Zhou P. et al. Randomized and double-blind controlled clinical trial of extracorporeal cardiac shock wave therapy for coronary heart disease. Heart Vessels. 2013; 28 (3): 284–91. DOI: 10.1007/s00380-012-0244-7
  21. Yu W., Shen T., Liu B., Wang S., Li J., Dai D. et al. Cardiac shock wave therapy attenuates H9c2 myoblast apoptosis by activating the AKT signal athway. Cell. Physiol. Biochem. 2014; 33 (5): 1293–303. DOI: 10.1159/000358697
  22. Liu B., Zhang Y., Jia N., Lan M., Du L., Zhao D., He Q. Study of the safety of extracorporeal cardiac shock wave therapy: observation of the ultrastructures in myocardial cells by transmission electron microscopy. J. Cardiovasc. Pharmacol. Ther. 2018; 23 (1): 79–88. DOI: 10.1177/1074248417725877

About Authors

  • Borbodoeva Bаktygul' Matikanovna, Cardiologist, orcid.org/0000-0001-8139-5742;
  • Asymbekova El'mira Umetovna, Dr. Med. Sc., Leading Researcher, orcid.org/0000-0002-5422-2069;
  • Matskeplishvili Simon Teymurazovich, Dr. Med. Sc., Corresponding Member of RAS, Chief Researcher, orcid.org/0000-0002-5670-167Х;
  • Akhmedyarova Nazli Kerimovna, Cand. Med. Sc., Researcher, orcid.org/0000-0001-7157-6312;
  • Sherstyannikova Ol'ga Mikhailovna, Cand. Med. Sc., Researcher, orcid.org/0000-0002-0340-695Х;
  • Tugeeva El'vira Faatovna, Dr. Med. Sc., Senior Researcher, orcid.org/0000-0003-1751-4924;
  • Buziashvili Victoriya Yur'evna, Cand. Med. Sc., Junior Researcher, orcid.org/0000-0001-6589-9246;
  • Buziashvili Yuriy Iosifovich, Dr. Med. Sc., Academician of RAS, Professor, orcid.org/000-0001-7016-7541

© Bakoulev National Medical Research Center for Cardiovascular Surgery,
Ministry of Health of the Russian Federation

Privacy Policy (in Russian)

Produced by
Bakoulev CCVS IT Departament